Apceth Biopharma GmbH, a leading company developing the next generation of cell-based therapies, announced the appointment of a new Supervisory Board.
The Supervisory Board will be responsible for advising and supporting the company on its corporate and business strategies. The Board is composed of highly experienced members with successful track records in the pharma and biotech industry.
Manfred Ruediger, Chairman, is a seasoned senior executive with over 20 years’ experience in leading biotech companies both at the management and board levels. He also has an extensive knowledge in advancing cell-based therapies towards late-stage clinical development and pre-commercialization stages.
Hans-Jochem Kolb is a world renowned expert in the field of hematological oncology and a pioneer in cellular immunotherapy and bone marrow/stem cell transplantation. He performed the first successful bone marrow transplantation in Germany and is active today as a consultant for various universities and biotech companies.
Matthias Kromayer is a member of the Executive Board of MIG Verwaltungs AG which is responsible for the MIG Funds’ life sciences holdings. He has a comprehensive background in strategic consulting and has advised more than 30 companies on their corporate strategy.
Klaus Schollmeier has more than 30 years’ experience as a senior executive and advisor in the biotech industry as well as in investment banking. He serves as board member of several European biotech companies.
“I am very pleased to welcome our new Supervisory Board, whose outstanding expertise and leadership will help us to successfully achieve our goals of bringing the next generation of cell-based gene therapies to patients with difficult to treat diseases,” said Christine Guenther, apceth Biopharma’s CEO.
“These are exciting times for apceth. apceth has been very successfully growing and expanding its profitable contract development and manufacturing business for cell-based therapeutics. At the same time, they are also advancing the development of their product candidate apceth-201 in graft-versus-host disease and apceth-301 in glioblastoma. Both diseases present huge unmet medical needs where innovative approaches are needed to change patients’ fates and they offer highly attractive commercial opportunities,” commented Manfred Ruediger, Chairman of the Supervisory Board, and added: “We look forward to working closely with Christine and her team to continue apceth’s growth and success.”
About apceth Biopharma GmbH
apceth Biopharma is a leading company in cell-based gene therapeutics with an innovative portfolio of drug candidates for the treatment of chronic inflammation, autoimmunity (immunomodulation) and solid cancer (immuno-oncology). Through introduction of different therapeutic transgenes into Mesenchymal Stem Cells (MSCs), apceth is developing two potent next generation MSC-based gene therapy products. apceth-201 expresses the immunomodulatory protein Alpha-1 Antitrypsin for the treatment of graft-versus-host disease. The company’s second program, apceth-301, expresses a potent immunostimulatory “cocktail” of cytokines which locally activates the immune system to eradicate tumor cells. apceth-301 is currently being developed for glioblastoma.
apceth is also an experienced and certified Contract Development & Manufacturing Organization for Advanced Therapy Medicinal Products (ATMPs) with a high international reputation for professionalism, quality and reliability. The company has state-of-the-art manufacturing facilities (ISO 5, ISO 7, ISO 8, BSL2 cleanrooms), is certified for GMP production, and has an extensive quality management system, allowing apceth to ensure full regulatory compliance as well as the utmost GMP and quality standards according to regulatory requirements for ATMPs. apceth has successfully obtained multiple manufacturing licenses for different types of native and genetically engineered cells and cell-based products. apceth was the first company worldwide to obtain approval for the clinical testing of genetically engineered MSCs in patients. Irrespectively of the type of cells and cell products (native or genetically engineered HSCs, MSCs, and immune cells), or the cell source, apceth provides fully customized solutions in the development and production of every customer product and process. Located centrally in the heart of Europe, apceth can perform efficient and fast supply of the client’s products across the continent.